Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma

Christos Demosthenous, Jing Jing Han, Mary J. Stenson, Matthew J. Maurer, Linda E. Wellik, Brian Link, Kristen Hege, Ahmet Dogan, Eduardo Sotomayor, Thomas Elmer Witzig, Mamta Gupta

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Deregulated mRNA translation has been implicated in disease development and in part is controlled by a eukaryotic initiation complex eIF4F (composed of eIF4E, eIF4G and eIF4A). We demonstrate here that the cap bound fraction from lymphoma cells was enriched with eIF4G and eIF4E indicating that lymphoma cells exist in an activated translational state. Moreover, 77% (110/142) of diffuse large B cell lymphoma tumors expressed eIF4E and this was associated with an inferior event free survival. Overexpression of wild-type eIF4E (eIF4E<sup>WT</sup>) but not cap-mutant eIF4E (eIF4E<sup>cap mutant</sup>) increased the activation of the eIF4F complex. Treatment with the active -site dual mTOR inhibitor CC214-1 reduced the level of the eIF4F complex by decreasing the cap bound fraction of eIF4G and increasing the levels of 4E-BP1. CC214-1 inhibited both the cap dependent and global protein translation. CC214-1 inhibited c-Myc, and cyclin D3 translation by decreasing polysomal fractions from lymphoma cells. Inhibition of eIF4E with shRNA further decreased the CC214-1 induced inhibition of the eIF4F complex, c-Myc, cyclin D3 translation, and colony formation. These studies demonstrate that the eIF4F complex is deregulated in aggressive lymphoma and that dual mTOR therapy has therapeutic potential in these patients.

Original languageEnglish (US)
Pages (from-to)9488-9501
Number of pages14
JournalOncotarget
Volume6
Issue number11
StatePublished - 2015

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Phosphotransferases
Cyclin D3
Protein Biosynthesis
Lymphoma, Large B-Cell, Diffuse
Therapeutics
Small Interfering RNA
Disease-Free Survival
Catalytic Domain
6-(4-(1H-1,2,4-triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo(4,5-b)pyrazin-2(3H)-one
Neoplasms

Keywords

  • &eIF4E
  • CC214-1
  • Dual mTOR inhibitors
  • Lymphoma
  • Translation initiation complex

ASJC Scopus subject areas

  • Oncology

Cite this

Demosthenous, C., Han, J. J., Stenson, M. J., Maurer, M. J., Wellik, L. E., Link, B., ... Gupta, M. (2015). Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget, 6(11), 9488-9501.

Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. / Demosthenous, Christos; Han, Jing Jing; Stenson, Mary J.; Maurer, Matthew J.; Wellik, Linda E.; Link, Brian; Hege, Kristen; Dogan, Ahmet; Sotomayor, Eduardo; Witzig, Thomas Elmer; Gupta, Mamta.

In: Oncotarget, Vol. 6, No. 11, 2015, p. 9488-9501.

Research output: Contribution to journalArticle

Demosthenous, C, Han, JJ, Stenson, MJ, Maurer, MJ, Wellik, LE, Link, B, Hege, K, Dogan, A, Sotomayor, E, Witzig, TE & Gupta, M 2015, 'Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma', Oncotarget, vol. 6, no. 11, pp. 9488-9501.
Demosthenous C, Han JJ, Stenson MJ, Maurer MJ, Wellik LE, Link B et al. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget. 2015;6(11):9488-9501.
Demosthenous, Christos ; Han, Jing Jing ; Stenson, Mary J. ; Maurer, Matthew J. ; Wellik, Linda E. ; Link, Brian ; Hege, Kristen ; Dogan, Ahmet ; Sotomayor, Eduardo ; Witzig, Thomas Elmer ; Gupta, Mamta. / Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. In: Oncotarget. 2015 ; Vol. 6, No. 11. pp. 9488-9501.
@article{a80624d4dcc343118ebeaec748eaaae2,
title = "Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma",
abstract = "Deregulated mRNA translation has been implicated in disease development and in part is controlled by a eukaryotic initiation complex eIF4F (composed of eIF4E, eIF4G and eIF4A). We demonstrate here that the cap bound fraction from lymphoma cells was enriched with eIF4G and eIF4E indicating that lymphoma cells exist in an activated translational state. Moreover, 77{\%} (110/142) of diffuse large B cell lymphoma tumors expressed eIF4E and this was associated with an inferior event free survival. Overexpression of wild-type eIF4E (eIF4EWT) but not cap-mutant eIF4E (eIF4Ecap mutant) increased the activation of the eIF4F complex. Treatment with the active -site dual mTOR inhibitor CC214-1 reduced the level of the eIF4F complex by decreasing the cap bound fraction of eIF4G and increasing the levels of 4E-BP1. CC214-1 inhibited both the cap dependent and global protein translation. CC214-1 inhibited c-Myc, and cyclin D3 translation by decreasing polysomal fractions from lymphoma cells. Inhibition of eIF4E with shRNA further decreased the CC214-1 induced inhibition of the eIF4F complex, c-Myc, cyclin D3 translation, and colony formation. These studies demonstrate that the eIF4F complex is deregulated in aggressive lymphoma and that dual mTOR therapy has therapeutic potential in these patients.",
keywords = "&eIF4E, CC214-1, Dual mTOR inhibitors, Lymphoma, Translation initiation complex",
author = "Christos Demosthenous and Han, {Jing Jing} and Stenson, {Mary J.} and Maurer, {Matthew J.} and Wellik, {Linda E.} and Brian Link and Kristen Hege and Ahmet Dogan and Eduardo Sotomayor and Witzig, {Thomas Elmer} and Mamta Gupta",
year = "2015",
language = "English (US)",
volume = "6",
pages = "9488--9501",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

TY - JOUR

T1 - Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma

AU - Demosthenous, Christos

AU - Han, Jing Jing

AU - Stenson, Mary J.

AU - Maurer, Matthew J.

AU - Wellik, Linda E.

AU - Link, Brian

AU - Hege, Kristen

AU - Dogan, Ahmet

AU - Sotomayor, Eduardo

AU - Witzig, Thomas Elmer

AU - Gupta, Mamta

PY - 2015

Y1 - 2015

N2 - Deregulated mRNA translation has been implicated in disease development and in part is controlled by a eukaryotic initiation complex eIF4F (composed of eIF4E, eIF4G and eIF4A). We demonstrate here that the cap bound fraction from lymphoma cells was enriched with eIF4G and eIF4E indicating that lymphoma cells exist in an activated translational state. Moreover, 77% (110/142) of diffuse large B cell lymphoma tumors expressed eIF4E and this was associated with an inferior event free survival. Overexpression of wild-type eIF4E (eIF4EWT) but not cap-mutant eIF4E (eIF4Ecap mutant) increased the activation of the eIF4F complex. Treatment with the active -site dual mTOR inhibitor CC214-1 reduced the level of the eIF4F complex by decreasing the cap bound fraction of eIF4G and increasing the levels of 4E-BP1. CC214-1 inhibited both the cap dependent and global protein translation. CC214-1 inhibited c-Myc, and cyclin D3 translation by decreasing polysomal fractions from lymphoma cells. Inhibition of eIF4E with shRNA further decreased the CC214-1 induced inhibition of the eIF4F complex, c-Myc, cyclin D3 translation, and colony formation. These studies demonstrate that the eIF4F complex is deregulated in aggressive lymphoma and that dual mTOR therapy has therapeutic potential in these patients.

AB - Deregulated mRNA translation has been implicated in disease development and in part is controlled by a eukaryotic initiation complex eIF4F (composed of eIF4E, eIF4G and eIF4A). We demonstrate here that the cap bound fraction from lymphoma cells was enriched with eIF4G and eIF4E indicating that lymphoma cells exist in an activated translational state. Moreover, 77% (110/142) of diffuse large B cell lymphoma tumors expressed eIF4E and this was associated with an inferior event free survival. Overexpression of wild-type eIF4E (eIF4EWT) but not cap-mutant eIF4E (eIF4Ecap mutant) increased the activation of the eIF4F complex. Treatment with the active -site dual mTOR inhibitor CC214-1 reduced the level of the eIF4F complex by decreasing the cap bound fraction of eIF4G and increasing the levels of 4E-BP1. CC214-1 inhibited both the cap dependent and global protein translation. CC214-1 inhibited c-Myc, and cyclin D3 translation by decreasing polysomal fractions from lymphoma cells. Inhibition of eIF4E with shRNA further decreased the CC214-1 induced inhibition of the eIF4F complex, c-Myc, cyclin D3 translation, and colony formation. These studies demonstrate that the eIF4F complex is deregulated in aggressive lymphoma and that dual mTOR therapy has therapeutic potential in these patients.

KW - &eIF4E

KW - CC214-1

KW - Dual mTOR inhibitors

KW - Lymphoma

KW - Translation initiation complex

UR - http://www.scopus.com/inward/record.url?scp=84928735563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928735563&partnerID=8YFLogxK

M3 - Article

C2 - 25839159

AN - SCOPUS:84928735563

VL - 6

SP - 9488

EP - 9501

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -